The present invention relates to a novel method for treating a patient that has
osteoporosis and the patient may be having administered cyclase activating parathyroid
hormone (CAP) or analogues. The patient receives an administration of a cyclase
inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from
between (SEQ ID NO:1 [PTH2-84]) and (SEQ ID NO:3 [PTH34-84])
(i.e., a contiguous portion of PTH having an amino acid sequence set forth in SEQ
ID NO:5 (PTH1-84), having the N-terminal amino acid residue starting
at any position spanning from position 2 through position 34 of the PTH1-84,
and the C-terminal amino acid residue ending at position 84 of the PTH1-84),
(preferably (SEQ ID NO:2 [PTH3-84]) and (SEQ ID NO:8 [PTH28-84])),
or a conservatively substituted variant thereof exhibiting parathyroid hormone
(PTH) antagonist activity in a therapeutically effective, but non-toxic amount
that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting
from the administration of CAP, and yet, through a CAP rebound effect, is effective
in itself in the treatment of osteoporosis.
